Compare · NNNN vs VNRX
NNNN vs VNRX
Side-by-side comparison of Anbio Biotechnology (NNNN) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.48B, about 206.6x VNRX ($12.0M).
- Over the past year, NNNN is up 111.7% and VNRX is down 87.9% - NNNN leads by 199.6 points.
- VNRX has been more active in the news (7 items in the past 4 weeks vs 1 for NNNN).
- VNRX has more recent analyst coverage (4 ratings vs 0 for NNNN).
PerformanceNNNN+111.73%VNRX-88.39%
2025-06-09+0.00%2026-06-08
- Company
- Anbio Biotechnology
- VolitionRX Limited
- Price
- $18.23-34.52%
- $1.33-3.61%
- Market cap
- $2.48B
- $12.0M
- 1M return
- -30.41%
- -41.19%
- 1Y return
- +111.73%
- -87.89%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2025
- 2015
- News (4w)
- 1
- 7
- Recent ratings
- 0
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
Latest VNRX
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Announces Pricing of $4.6 Million Public Offering
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
- SEC Form DEF 14A filed by VolitionRX Limited
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement
- VolitionRX Limited filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form SCHEDULE 13G/A filed by VolitionRX Limited
- SEC Form 10-Q filed by VolitionRX Limited